T he functional properties of muscle fibers vary considerably between different muscles. 1 The extraocular muscles (EOMs) are among the most complex muscles in the body and have been considered a separate muscle allotype, 2 due to their special features. The EOMs contain fibers with a wide array of contractile properties, varying from extremely fast to fibers capable of sustained, tonic contractions. Previously, we sought to elucidate the molecular basis of this unique allotype of human EOMs at the fiber level, [3] [4] [5] by determining the patterns of expression of myosin heavy chain (MyHC; the major determinant of heterogeneity of contraction force and velocity 6, 7 ) and of SERCA-1 and -2 (determinants of the relaxation rate 8 ). The fibers in the human EOMs have very complex MyHC composition patterns, with most fibers containing more than one MyHC isoform. Moreover, differences in the relative amounts of a given MyHC isoform are typically observed among fibers sharing a particular combination of isoforms. 3 Despite this heterogeneity, the fibers in the human EOMs can be divided grossly into three major fiber groups, based on their content of MyHCI, MyHCIIa, and MyHCeom. 3 Myosin-binding protein C (MyBP-C) is, next to myosin, the second most abundant thick-filament protein in striated muscles. 9 It is located in the A band, in a restricted part of the cross-bridge-bearing region. 10 MyBP-C is a Ϸ130 kDa protein and both its C terminus and N terminus bind to myosin. 11, 12 MyBP-C is presumed to have a regulatory, although not essential, role in sarcomere assembly 13, 14 and to play a physiological role in regulating contraction by modulating unloaded shortening velocity. 15 The importance of MyBP-C for muscle function is indicated by the fact that mutations in the gene for cardiac MyBP-C (MyBP-C-card) cause familial hypertrophic cardiomyopathy. 16 -18 There are three major isoforms of MyBP-C in human muscle: fast skeletal (MyBP-C-fast), slow skeletal (MyBP-C-slow), and MyBP-C-card. 19 MyBP-C-fast, detected both with in situ hybridization and immunocytochemistry, is present in fast fibers, whereas MyBP-C-slow is present in both slow and fast fibers, in human skeletal muscle. 20 The cardiac isoform is restricted to the heart and has never been detected in conjunction with any other MyBP-C isoforms in cardiac or skeletal muscle. 20 The three human MyBP-C genes have been mapped and sequenced. [21] [22] [23] Recent analysis of single fibers by SDS-PAGE, revealed the coordinated expression of MyBP-C-slow in fibers containing MyHCI (slow); MyBP-C-fast in fibers with MyHCIIx (fast); and an additional isoform, MyBP-C-intermediate, in fibers containing MyHCIIa (fast) in human limb muscle. 24 Coordinated isoform changes, indicating that MyBP-C expression is linked to MyHC expression, have been reported during skeletal muscle hypertrophy in the rat. 25 However, in the human masseter, a masticatory muscle with rather unique properties, 26 -28 the very complex MyHC composition of its fibers was not paralleled by an intricate MyBP-C pattern. 24 Data on the MyBP-C composition of human EOMs and its correlation to the MyHC composition at the protein and cellular level are lacking. In the present study, we investigated the distribution of the fast and slow isoforms of MyBP-C in relation to the MyHC profile of the fibers and found further evidence of the uniqueness of the molecular portfolios of the fibers in the human EOMs.
MATERIAL AND METHODS
The muscles were collected according to the ethical recommendations of the Swedish Transplantation Law, with the approval of the Medical Ethics Committee, Umeå University, and in compliance with the Declaration of Helsinki for research involving human tissue. Seventeen EOM samples were obtained at autopsy from six men and one woman (ages, 17, 26, 27, 34, 34, 81 and 86 years) who had had no known neuromuscular disease. The samples were mounted on cardboard, rapidly frozen in propane chilled with liquid nitrogen, and stored at Ϫ80°C until used.
SDS-PAGE and Immunoblots
Whole-muscle extracts were prepared from one rectus superior, one rectus lateralis, two obliquus superior, one levator palpebrae (LP), and one brachioradialis muscle, as previously described. 29 MyBP-C isoforms were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 4% (wt/vol) stacking and 8% running gels. Gel buffer solutions included 10% glycerol. 24 Proteins were identified on the basis of their molecular mass, immunoreactivity, and order of migration in comparison with purified rabbit MyBP-C-fast and reference samples prepared from one vastus lateralis muscle with mostly type 1 (slow-twitch) fibers and one vastus lateralis muscle with mostly type 2 (fast-twitch) fibers, as well as cultured human skeletal muscle cells rich in MyBP-C-fast. 30, 31 The separating gels (160 ϫ 180 ϫ 0.75 mm) were silver stained and subsequently scanned. For immunoblot analysis, the separated proteins were transferred onto nitrocellulose sheets and incubated with antibodies against MyBP-C-slow and -fast (Table 1) .
Immunocytochemistry
The samples for immunocytochemistry were taken from the rectus superior (n ϭ 5), rectus inferior (n ϭ 2), rectus medialis (n ϭ 2), rectus lateralis (n ϭ 2), and obliquus superior (n ϭ 2) muscles. Eight samples were taken from the middle portion of the muscle, two from the distal part (close to the bulb), and three from the proximal part (close to anulus tendineus) of the muscle. For comparison, samples were also taken from human myocardium, LP (n ϭ 2), biceps brachii, first dorsal interosseus, and vastus lateralis muscles.
Serial cross sections, 5 m thick, were processed for immunocytochemistry, with a panel of previously very well characterized monoclonal antibodies (mAb), recognizing MyBP-C and MyHC isoforms (Table 1). The tissue sections were processed as previously described, 32, 37 by using the indirect peroxidase complex (Dako, Copenhagen, Denmark) technique to visualize bound antibody.
Processed sections were photographed under a microscope equipped with a charge-coupled device (CCD) camera (Nikon, Tokyo, Japan). The overall staining pattern of each section was examined, and representative areas of each muscle sample, including the orbital and global layers, were studied in detail.
RESULTS

SDS-PAGE and Immunoblots
Both MyBP-C-slow and -fast were identified in the limb muscle samples by SDS-PAGE (Fig. 1A ) and in immunoblots (Fig. 1B) . In the EOMs, only MyBP-C-slow could be detected in the gels and immunoblots, whereas MyBP-C-fast and -intermediate were absent (Fig. 1 ).
Immunocytochemistry
Validation of Antibody Specificity. The mAbs against MyBP-C-fast and slow did not label sections of human myocardium, indicating that they do not cross-react with the MyBP-Ccard isoform.
Limb Muscles. Anti-MyBP-C-fast immunostained all fast fibers (containing MyHCIIa and/or MyHCIIx) strongly, whereas it did not label any fibers containing solely MyHCI (Fig. 2) . Anti-MyBP-C-slow stained all fibers strongly (Fig. 2) , in accordance with previous data.
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Extraocular Muscles. The antibodies against the different MyHC isoforms stained the EOMs heterogeneously (Fig. 3, 4 , 5). The MyHC composition of the individual fibers in the orbital and global layers was complex, because of the presence of multiple isoforms in each fiber and differences in the relative amounts of any given MyHC among the fibers. Three major groups of fibers were distinguished in both the orbital and global layers of the EOMs, according to their immunohistochemical staining patterns, as previously described 3 : (1) fast fibers that contain MyHCIIa and in addition may contain MyHCemb and/or MyHCeom; (2) slow fibers that contain MyHCI and may also contain MyHC-slow tonic, MyHC␣-cardiac, MyHCemb, and/or MyHCeom; and (3) MyHCeom pos /MyHCIIa negfibers that lack MyHCI and MyHCIIa, but contain MyHCeom and may in addition contain MyHCemb. Anti-MyBP-C-fast did not label any of the fibers in 11 of the EOM samples examined (Figs. 3B, 4B , 5B). However, in the proximal part of a rectus superior and of a rectus inferior muscle taken from the oldest subjects (81 and 86 years, respectively), this mAb labeled a few fibers weakly (Fig. 6 ). These stained fibers were mostly, but not exclusively, located in the periphery of the muscles. Many of them were also reactive to anti-MyHCIIa, but there was no clear correlation between the staining pattern of anti-MyHCIIa and anti-MyBP-C-fast.
Anti-MyBP-C-slow labeled all fibers (Figs. 3A, 4A, 5A ). The slow fibers were strongly stained, irrespective of whether they contained only MyHCI, MyHCIϩMyHCsto, or MyHCIϩ MyHCstoϩMyHC␣-cardiac (Figs. 4, 5) . The fast fibers (MyHCIIa) were labeled moderately to strongly with anti-MyBP-Cslow, whereas the MyHCeom pos /MyHCIIa neg -fibers were labeled lightly, moderately, or strongly by this mAb. At low magnification, the orbital layer appeared more heavily stained than the global layer, and the proximal and distal portions of the muscles appeared more stained than the middle portions, because the MyHCeom pos /MyHCIIa neg -fibers were more abundant in the global layer and in the midbelly region. No correlation was found between the staining pattern of anti-MyBP-Cslow and the presence or absence of MyHCemb, MyHCsto, or MyHC␣-cardiac in the fibers (Fig. 5) .
Levator Palpebrae. Anti-MyBP-C-fast labeled some of the fast fibers and the MyHCeom pos /MyHCIIa neg fibers in the LP heterogeneously. The fibers containing MyHCI were not stained with anti-MyBP-C-fast. Anti-MyBP-C-slow labeled all fibers strongly, with less heterogeneity than in the EOMs (Fig. 7) .
DISCUSSION
The most important result of the present study is the striking difference in the MyBP-C composition between human EOM fibers and limb muscle, a finding that lends further support to the uniqueness of the EOMs as a separate muscle allotype. In addition, the present results further confirm the phenotype of the LP muscle as intermediate between that of the true EOMs 5 and 7) . M, molecular mass standard; RM, rectus medialis; BR, brachioradialis; OS, obliquus superior; C, cultured human muscle cells rich in MyBP-C-fast. 
(B) Immunoblots treated with the antibodies against MyBP-C-slow (lanes 1-4) and -fast (lanes 5-8). No immunoreactivity was detected with anti-MyBP-C in the EOM samples (lanes
MyHC versus MyBP-C Composition
Human limb muscle fibers contain MyHCI, MyHCIIa, or MyHCIIx and occasional hybrid fibers contain two of these isoforms (I ϩIIa or IIaϩIIx). 40 Coordinated expression patterns for MyHC and MyBP-C isoforms have been reported for rat limb muscle in hypertrophy 25 and for single human limb muscle fibers studied with SDS-PAGE, 24 meaning that MyBP-C-fast dominates in fibers expressing MyHCIIx, MyBP-C-intermediate dominates in fibers containing MyHCIIa, and MyPB-C-slow correlates with a content of MyHC I. 24 Our results confirm previous data in human limb muscle. 20, 24 Moreover, we showed in the present study that there is no such coordination between MyHC and MyBP-C isoforms in the human EOMs. We were unable to detect MyBP-C-fast or intermediate in most of the fibers of the EOMs, although these muscles have a predominance of fast fibers when examined on the basis of their myosin heavy chain reactivity (71% of the fibers contain MyHCIIa and 13% are MyHCeom pos /MyHCIIa neg fibers 3 ) and they are among the fastest muscles in the body. This is an additional feature that further strengthens the identity of the EOMs as a separate allotype, distinct from limb muscle. In the masseter muscle, a member of the masticatory allotype, only one MyBP-C isoform, with a molecular mass similar to slow MyBP-C, was identified in single fibers with SDS-PAGE, irrespective of their MyHC composition. 24 Whether this MyBP-C isoform detected in the masseter is identical with MyBP-C-slow or an additional isoform remains to be investigated. 24 The MyHC composition of the fibers in the human EOMs and in the masseter is very complex. Most, if not all the fibers in the EOMs contain more than one MyHC isoform, and in both EOMs and masseter fibers, up to five different MyHC isoforms have been identified, 3, 24, 26 including developmental and ␣-cardiac MyHC isoforms. 24, 26, 41 In addition to the MyHC isoforms detected in our study, transcripts of MyHCIIb are also present in human EOMs (Andersen J, Pedrosa-Domellöf F, personal communication, 2000) and the presence of MyHCIIx cannot be excluded. 
MyBP-C Composition
In the present study, SDS-PAGE, immunoblots, and immunocytochemistry all revealed that the human EOMs lacked MyBP-Cfast. Furthermore, microarray data confirm at the RNA level that the human EOMs differ significantly from limb muscles in the level of expression of MyBP-C-fast, which is downregulated more than 100-fold in EOMs. 42 All these findings indicate that MyBP-C-fast is absent or present in only trace amounts in the human EOMs. MyBP-C intermediate was not detected biochemically in the EOMs but the lack of a specific antibody does not allow us to explore whether it may be present in amounts below the level of detection with SDS-PAGE.
In contrast, at the RNA level, MyBP-C-slow appears to be essentially identical in human EOMs and limb muscle. 42 The MyBP-C-cardiac isoform has been detected only in heart muscle, 20, 43 and expression profiling of the human EOMs versus limb did not reveal the cardiac isoform to be part of the EOM allotype. 42 Multiple isoforms of MyBP-C have been identified in chicken, 44 but until now there is no evidence of the existence of isoforms other than MyBP-C-slow, -fast, -intermediate, and -cardiac in human muscle. Further studies with single-fiber SDS-PAGE in conjunction with genetic tools are needed to address the question of whether novel MyBP-C isoforms may exist in the human EOMs.
Our understanding of the function of MyBP-C is still rather limited, despite the fact that mutations on the cardiac isoform are responsible for familial hypertrophic cardiomyopathies. 16 -18 Recently, it has been shown that the S2 binding domain of MyBP-C is a modulator of contractility and that it works in a fashion that is at least partly independent of a "tether" with the MyHC molecule. 45 The lack of MyBP-C theoretically may result in higher contraction rates, since experimental extraction of MyBP-C leads to an increase in contraction rate and increases the Ca 2ϩ sensitivity of the force-velocity curve. 46 These changes were shown to be reversible by the readdition of MyBP-C.
The lack of MyBP-C at the single muscle fiber level may have an impact on regulation of muscle contraction at low levels of activation in vivo. This notion is supported by in vitro experiments demonstrating an increase in the low-velocity phase of shortening at submaximal Ca 2ϩ activation levels 15 and increase the Ca 2ϩ sensitivity of force 46 after chemical extraction of endogenous MyBP-C from skinned skeletal muscle fibers. The effects of removal of MyBP-C on regulation of contraction have been interpreted to be secondary to removal of a structural constraint of MyBP-C on the myosin S-1 domain leading to increased cross-bridge binding. Thus, lack of MyBP-C is expected to reduce an internal load on the myosin head, resulting in increased shortening velocity. Single-fiber experiments are needed to elucidate the role of MyBP-C on the contractile properties of the different fiber types in the human EOMs. However, the very small size of the EOM fibers poses a technical challenge in performing such experiments.
Levator Palpebrae
We have previously shown that the human LP muscle shares common features with the true EOMs (e.g., loosely arranged fibers and the presence of MyHC␣-cardiac, MyHCemb, and MyHCeom), but has a phenotype that is intermediate between the EOMs and the limb muscles (e.g., intermediate fiber size, lack of organization into layers, and lack of MyHCsto). 3 In the present study, immunocytochemistry indicates the presence of MyBP-C-slow in all fibers and MyBP-C-fast in some fast fibers. Taken together, these findings further confirm the phenotype of the LP as intermediate between that of the EOMs and the limb muscles. 
